
Rocket Lab shares are down 55% from their May peak (to ~$67.50) as the space-stock selloff intensifies, but the article warns the stock still looks expensive. The company is pursuing a potentially transformative $8B acquisition of Iridium to accelerate competition with SpaceX’s Starlink and secure L-band spectrum rights; Iridium would add $871M in revenue vs. Rocket Lab’s ~$680M trailing 12-month revenue (up 1,000% over five years). Despite the growth narrative, the stock trades at an extreme ~55x price-to-sales, implying valuation risk even if revenue grows >10x—leading the author to advise waiting for a further pullback.
The market is still valuing RKLB as if it can compound into a platform monopoly while simultaneously funding the capital intensity of launch, spacecraft, and comms. That combination usually breaks at the financing step: any acquisition-led strategy that lifts revenue today can still destroy equity value if it forces dilution, leverage, or a longer path to free cash flow than the market is pricing. The key second-order risk is that “strategic optionality” becomes a permanent excuse for paying top-tier software multiples on hardware economics.
Over the next 1-3 months, the catalyst path is not revenue growth but deal structure, regulatory friction, and management guidance on integration and cash burn. If the transaction is financed with stock, RKLB likely faces multiple compression because investors will re-underwrite it as a more complex, lower-margin conglomerate rather than a pure-space growth story. A failed or delayed deal would likely hurt less than an overextended close, because the current valuation leaves little room for execution slippage.
Contrarian take: the consensus is focused on TAM expansion, but the more important variable is whether the company can produce repeatable gross margin and FCF before the market’s patience runs out. The better expression may be to own the target asset if the spread is wide enough and short the acquirer into any pop; the market is rewarding ambition more than economics, and that usually reverses when financing terms are disclosed. The thesis is falsified if RKLB proves it can sustain accelerated revenue without dilution and with improving operating leverage over the next two earnings cycles.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
mildly negative
Sentiment Score
-0.25
Ticker Sentiment